CMC変更前後のGZR18注射液の生物学的同等性試験
健康な成人男性被験者におけるCMC変更前後のGZR18注射液の生物学的同等性を評価するための無作為化、オープンラベル、単回投与、並行比較試験
This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects.
The study is divided into 3 parts, each of which evaluates the bioequivalence of GZR18 Injection for one strength before and after CMC changes.
Subjects eligible for each part of the screening will be randomized into Group A or Group B in a 1:1 ratio. Each subject will receive a single dose of GZR18 Injection, followed by PK blood sampling and safety follow-up for 35 days. Subjects will be admitted to the hospital 1 day predose, follow a standardized light diet that evening, and then fast for at least 10 h thereafter. On the day of administration, GZR18 Injection of a single strength will be administered subcutaneously under fasting conditions at a site approximately two finger-widths (2.5 cm) away from the umbilicus on the abdomen. Lunch and dinner will be served approximately 3 and 9 h postdose, respectively.
Venous blood will be collected at 14 time points for GZR18 plasma concentration analysis: at 0 h (within 60 min predose) and 1, 6, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, and 840 h postdose.
Subjects will undergo corresponding laboratory safety tests at screening, D36, and early withdrawal visits.
During the entire study period, subjects should maintain a light diet, avoid strenuous exercise, and refrain from consuming juice, caffeinated beverages (such as tea and coffee), and alcoholic drinks. Smoking and any other activities that may affect PK observation or safety evaluations are strictly prohibited.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Suzhou
-
Suzhou、Suzhou、中国
- The Second Affiliated Hospital of Soochow University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Subjects who voluntarily sign the Informed Consent Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.
-
Male, 18 to 50 years of age at signing the ICF (both inclusive).
-
Weight ≥ 50 kg and body mass index (BMI) within 19-26 kg/m2 (inclusive) at screening.
-
Subjects of childbearing potential with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm donation.
-
Exclusion Criteria:
-
Subjects with clinically significant abnormalities detected during the screening period in physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal ultrasound, or chest X-ray, as determined by the investigator.
-
Subjects who test positive for hepatitis B virus surface antigen, hepatitis C virus IgG antibody, human immunodeficiency virus antibody, P24 antigen, or anti-treponema pallidum antibody.
-
Subjects with a history of or existing circulatory, urinary, digestive, respiratory, nervous, endocrine, or psychiatric disorders that, in the investigator's judgment, remain clinically significant.
-
History of acute or chronic pancreatitis and pancreatic injury before screening.
-
History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.
-
Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before randomization.
-
Subjects with severe infection or unexplained infection within 4 weeks before screening.
-
Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.
-
Subjects known or suspected to have hypersensitivity to any ingredient of the investigational medicinal product (IMP) (glucagon like peptide-1 receptor agonist (GLP-1RA) or its excipients).
-
Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicine within 2 weeks prior to screening; use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists (such as GLP-1R/glucagon receptor [GCGR] agonists or gastric inhibitory polypeptide receptor [GIPR]/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists) within 3 months prior to screening.
-
Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.
-
Blood donation or blood loss greater than or equal to 400 mL within 3 months before screening, or blood donation scheduled during the study or within 8 weeks after the end of the study.
-
History of drug abuse prior to screening; or positive results for drug abuse at screening (D-1).
-
History of alcohol abuse within 3 months prior to screening, defined as an average intake of more than 14 units per week (1 standard unit=360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits); or use of any alcohol-containing products 48 hours before administration; or abnormal results for breath alcohol test at screening (D-1).
-
Subjects who smoked more than 5 cigarettes per day on average within the 3 months before screening, or who do not agree to abstain from smoking for the duration of the study.
-
Subjects who engage in strenuous exercise within 48 h before administration of the IMP, or have other factors that may affect drug absorption, distribution, metabolism, or excretion.
-
Subjects who consume grapefruit or grapefruit-containing products, or any caffeinated or xanthine-containing foods or beverages (such as coffee, tea, cola, or chocolate) within 48 hours before administration of the IMP.
-
Subjects who have special dietary requirements and cannot adhere to a standardized diet, or who are lactose intolerant.
-
Subjects with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venous blood collection.
-
Subjects who are investigators or employees of the study site, or family members of the employees or investigators.
-
Participation in a clinical study of another IMP or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP or device before completing all scheduled assessments in the clinical study.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:GZR18注射A2
|
Administered SC |
|
実験的:GZR18注射B2
|
Single dose, s.c. |
|
実験的:GZR18注射A3
|
Administered SC |
|
実験的:GZR18注射液B3
|
Single dose, s.c. |
|
実験的:GZR18 injection A1
Single dose, s.c. |
Administered SC |
|
実験的:GZR18 injection B1
Single dose, s.c. |
Single dose, s.c. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
最大血中濃度(Cmax)
時間枠:1日目-36日目
|
1日目-36日目
|
|
投与間隔中の濃度-時間曲線下面積 (AUC0-t)
時間枠:Day1-Day36
|
Day1-Day36
|
|
投与時から無限大まで外挿した濃度-時間曲線下面積(AUC0-∞)
時間枠:1日目~36日目
|
1日目~36日目
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
最終時点から外挿したAUCの無限大への外挿のAUC0-∞に対する割合(AUC_%Extra)
時間枠:1日目~36日目
|
1日目~36日目
|
|
最大血中濃度到達時間 (Tmax)
時間枠:Day1-Day36
|
Day1-Day36
|
|
消失半減期 (t1/2)
時間枠:Day1-Day36
|
Day1-Day36
|
|
末期相における血漿濃度の消失速度定数 (λz)
時間枠:1日目~36日目
|
1日目~36日目
|
|
治療関連有害事象(TEAEs)
時間枠:Day1-Day36
|
Day1-Day36
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- GZR18-OOO-108
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。